达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察

doi:10.3969/j.issn.1003-9198.2024.10.013

Abstract

Abstract: Objective To investigate the efficacy of dapagliflozin in the elderly patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM) who underwent percutaneous coronary intervention (PCI). Methods The clinical data of 80 elderly patients with coronary heart disease complicated with T2DM and HFrEF who were hospitalized in Department of Cardiovascular Medicine of Anqing Municipal Hospital from November 2019 to November 2022 were retrospectively analyzed.The patients were divided into dapagliflozin group (n=44) and control group (n=36) according to whether they used dapagliflozin or not. The incidence of major adverse cardiovascular events (MACEs) during hospitalization and follow-up period was recorded and analyzed in each group. Results There were no significant differences in the clinical baseline data between the two groups (P>0.05). However, the overall incidence rate of MACEs was significantly lower in dapagliflozin group than that in control group (4.54% vs. 19.44%, P=0.036). Cox regression analysis showed that the use of dapagliflozin was a strong protective factor for MACEs in the elderly patients with HFrEF complicated with T2DM (HR=0.030, 95%CI:0.010-0.921). Conclusions Dapagliflozin is a protective factor in the elderly patients with HFrEF complicated with T2DM undergoing PCI,which could reduce the incidence rate of medium and long-term MACEs.

Key words: dapagliflozin, coronary heart disease, type 2 diabetes mellitus, heart failure with reduced ejection fraction

CLC Number:

GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure[J]. Practical Geriatrics, 2024, 38(10): 1025-1029.

References

[1] ZHU J, YU X, ZhENG Y, et al. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map[J]. Lancet Diabetes Endocrinol, 2020, 8(3): 192-205.
[2] SI Y, FAN W, SHAN W, et al. Association between triglyceride glucose index and coronary artery disease with type 2 diabetes mellitus in middle-aged and elderly people[J]. Medicine, 2021, 100(9): e25025.
[3] WIVIOTT S D, RAZ I, BONACA M P, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.
[4] VAN B E, SMITS M M, UITER D, et al. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes[J]. J Hypertens, 2020, 38(9): 1811-1819.
[5] FILION K B, LIX L M, YU O H, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study[J]. BMJ, 2020, 370: m3342.
[6] 王广兴, 龙清霞, 张芝帅. 达格列净片治疗冠心病合并2型糖尿病患者的效果分析[J]. 中国实用医药, 2020, 15(26): 126-128.
[7] HEERSPINK H J, PERKINS B A, FITCHETT D H, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J]. Circulation, 2016, 134(10): 752-772.
[8] MAGAVERN E, KHONG T K. Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes[J]. Drug Ther Bull, 2021, 59(2): 22-23.
[9] MCMURRAY J, SOLOMON S D, INZUCCHI S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008.
[10] ZANNAD F, FERREIRA J P, POCOCK S J, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials[J]. Lancet, 2020, 396(10254): 819-829.
[11] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志, 2014, 22(8): 2-42.
[12] BAILEY C J, GROSS J L, PIETERS A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2010, 375(9733): 2223-2233.
[13] DAWWAS G K, SMITH S M, PARK H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2019, 21(1): 28-36.
[14] BERG D D, JHUND P S, DOCHERTY K F, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction[J]. JAMA Cardiol, 2021, 6(5): 499-507.

Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Metrics

Recommended 10

[1]	GAO Yuan, CHEN Hua, CHEN Ke, HUANG Wenlong. Relationship of bone mineral density and fracture risk with type 2 diabetes mellitus-related factors in elderly patients [J]. Practical Geriatrics, 2024, 38(9): 911-915.
[2]	DAI Jing, CUI Yan. Correlation between glycosylated hemoglobin variability and cognitive dysfunction in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(9): 931-935.
[3]	XIANG Chao, LUO Caidong. Analysis of the diagnostic value of T wave change of avL lead for the degree of coronary artery stenosis in elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(8): 788-791.
[4]	SHAN Zhuzi, WANG Xuefei, WU Haidi, LIU Dongmei, JIANG Hua, TANG Wei, MO Yongzhen, CUI Yan. Study on the relationship between percentage of body fat and blood glucose fluctuation in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(7): 693-696.
[5]	ZHANG Jingjing, ZHU Xiaoxia, YAO Chunlei, WANG Wei. Correlation between control nutritional status score and heart failure in elderly patients with coronary artery disease [J]. Practical Geriatrics, 2024, 38(7): 697-700.
[6]	SHI Wen, ZHU Ping, ZHOU Jie, YAN Ting, HUANG Yujie, YAN Yan. Effect of pancreatic kallidinogenase on mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(6): 587-591.
[7]	GUO Chun, YI Mengting, ZONG Qianxing, ZHOU Yi, WU Haidi, MO Yongzhen. Development of a 6-month risk prediction model for hypoglycemia in elderly patients with type 2 diabetes mellitus: a longitudinal study [J]. Practical Geriatrics, 2024, 38(6): 592-597.
[8]	LIU Qianhui, YAO Zijun, HE Yuli, XU Yunfan, WU Jun. Effects of HbA1c level on cardiac structure and function in elderly patients with type 2 diabetes mellitus and chronic heart failure [J]. Practical Geriatrics, 2024, 38(5): 491-437.
[9]	ZHA Zhimin, LIU Huan, WANG Xiangming, LI Qiushuang, GUO Yan. Effect of cardiac valve calcification on prognosis of elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(3): 245-250.
[10]	TANG Yuan, DENG Shufang, HE Yongmei, DAI Yuxuan, LUO Jing. The status of health literacy and correlation with frailty in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(3): 255-259.
[11]	WANG Su, ZHAO Yijing, WEI Chenmin, CHEN Kun, CAO Wen, WANG Kun, YANG Yu. Correlation of triglyceride-glucose index with low-density lipoprotein subtypes in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2024, 38(10): 1002-1006.
[12]	ZHU Jian-Yi, LV Zhi-Gang, SHI Heng-Chuan. Relationship of serum total homocysteine and macrovascular diseases in elderly patients with type 2 diabetes mellitus [J]. Practical Geriatrics, 2010, 24(2): 135-137.
[13]	HU Lan-Ping, GU Ping, WANG Jian, SHAO Jia-Qiang, DU Hong, WANG Yang-Tian, LU Bin, PENG Li. Determination of islet autoantibodies in elderly diabetic patients by immunoblotting test [J]. Practical Geriatrics, 2010, 24(2): 156-158.